HANGZHOU BIOTEST BIOTECH CO.,LTD. Hangzhou Biotest Biotech Co.,Ltd. Share Price
Equities
688767
CNE1000050H0
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.64 CNY | +4.68% |
|
+12.71% | -5.38% |
| Sales 2022 | 1.9B 263M 21.91B | Sales 2023 | 442M 61.06M 5.09B | Capitalization | 3.23B 446M 37.2B |
|---|---|---|---|---|---|
| Net income 2022 | 774M 107M 8.92B | Net income 2023 | 107M 14.78M 1.23B | EV / Sales 2022 | 1.52 x |
| Net cash position 2022 | 2.03B 281M 23.42B | Net cash position 2023 | 1.9B 263M 21.94B | EV / Sales 2023 | 3 x |
| P/E ratio 2022 |
6.37
x | P/E ratio 2023 |
30.3
x | Employees | 730 |
| Yield 2022 |
4.76% | Yield 2023 |
-
| Free-Float | 33.12% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.68% | ||
| 1 week | +12.71% | ||
| 1 month | +11.01% | ||
| 3 months | +14.38% | ||
| 6 months | -1.92% | ||
| Current year | -5.38% |
1 week
26.69
28.96
1 month
22.8528.96
Current year
22.2331.36
1 year
22.2336.70
3 years
22.23152.50
5 years
22.23152.50
10 years
22.23152.50
| Managers | Title | Age | Since |
|---|---|---|---|
Shu Jiang Wu
CEO | Chief Executive Officer | 47 | 01/10/01 |
Miao Miao Yu
DFI | Director of Finance/CFO | 43 | 01/16/01 |
Dong Chen
CTO | Chief Tech/Sci/R&D Officer | 28 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yin Long Chen
CHM | Chairman | 62 | 28/15/28 |
Shu Jiang Wu
CEO | Chief Executive Officer | 47 | 01/10/01 |
Yu Jie Chen
BRD | Director/Board Member | 34 | 01/15/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 28.64 | +4.68% | 1,709,098 |
| 29/24/29 | 27.36 | +7.67% | 1,140,850 |
| 26/24/26 | 25.41 | +0.87% | 260,749 |
| 25/24/25 | 25.19 | +0.76% | 186,548 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.38% | 422M | |
| -1.89% | 12.56B | |
| -9.59% | 7.68B | |
| -1.31% | 5.29B | |
| +21.82% | 5.18B | |
| +0.02% | 4.57B | |
| -50.89% | 3.29B | |
| +6.42% | 2.6B | |
| -10.02% | 2.2B | |
| -8.29% | 1.79B |
- Stock Market
- Equities
- 688767 Stock
